01
Perceptual effects
Acute subjective effects may affect tolerability, blinding, setting and patient selection.
Preclinical CNS biotechnology · Austin, Texas
Next-generation neuroplastogens for practical psychiatric medicine.
Telesti Therapeutics is developing preclinical small-molecule programs designed to retain therapeutically relevant neuroplasticity while reducing the perceptual, safety and operational limitations associated with first-generation psychedelic compounds.
Lead program UL-01 · Preclinical lead optimization
The development problem
The biology may be compelling. The product still has to be practical.
Conventional psychedelic mechanisms can introduce perceptual effects, monitoring requirements and development liabilities that complicate broad clinical use. Telesti is evaluating whether differentiated small-molecule design can preserve relevant pharmacology while improving the path to a scalable medicine.
02
Operational burden
Long monitored visits and specialized delivery models can constrain reach and adoption.
03
Development liabilities
Receptor, cardiac, exposure, formulation and manufacturing risk must be separated and resolved.
Our design thesis
A disciplined route from molecule to candidate.
A compelling receptor profile is not enough. Telesti advances compounds through an integrated, exposure-linked framework spanning functional pharmacology, unbound brain exposure, translational activity, cardiovascular and systemic safety, and candidate-specific developability.
The objective is one development candidate and one genuinely distinct backup—not a broad collection of incompletely characterized leads.
01
Technical truth
Is the foundational package reproducible and decision-ready?
02
Pharmacology
Does the series retain the desired profile without an obvious liability?
03
Exposure
Can tolerated dosing achieve relevant unbound CNS exposure?
04
Translation & safety
Is activity separated from impairment and integrated safety risk?
05
Candidate & CMC
Can the molecule become a controlled, scalable clinical product?
Lead corporate program
Designed for differentiated neuroplasticity.
UL-01 is being evaluated across functional serotonergic pharmacology, neuroplasticity, CNS exposure, translational models, integrated cardiovascular risk and candidate-specific CMC.
Current objective checkpoint
Development-candidate nomination and a distinct backup supported by a candidate-specific regulatory plan.
Development discipline
Four systems. One candidate decision.
01
Functional pharmacology
Matched systems, reference compounds and explicit control of assay-dependent conclusions.
02
Exposure & translation
Unbound brain exposure and PK/PD—not nominal dose—anchor in-vivo interpretation.
03
Integrated safety
Functional 5-HT2B, ion channels and in-vivo cardiovascular risk are assessed separately and together.
04
Developability
Solid form, formulation, analytical control, process chemistry and material comparability are candidate-specific.
Company
Scientific ambition with decision discipline.
Telesti combines medicinal chemistry, CNS development strategy and stage-gated execution from Austin, Texas.
Uroš Laban, PhD
Co-founder & CSO
Medicinal chemistry and scientific strategy.
Graham Pilger
Co-founder & CEO
Strategy, financing, partnerships and program execution.
Work with Telesti
Serious science requires serious partners.
Telesti welcomes inquiries from investors, strategic partners, scientific advisors, government stakeholders, CROs and prospective team members.